Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
JNCI Cancer Spectr. 2021 Aug 31;5(5). doi: 10.1093/jncics/pkab077. eCollection 2021 Oct.
Smoking has been associated with colorectal cancer (CRC) incidence and mortality in previous studies, but current evidence on smoking in association with survival after CRC diagnosis is limited.
We pooled data from 12 345 patients with stage I-IV CRC from 11 epidemiologic studies in the International Survival Analysis in Colorectal Cancer Consortium. Cox proportional hazards regression models were used to evaluate the associations of prediagnostic smoking behavior with overall, CRC-specific, and non-CRC-specific survival.
Among 12 345 patients with CRC, 4379 (35.5%) died (2515 from CRC) over a median follow-up time of 7.5 years. Smoking was strongly associated with worse survival in stage I-III patients, whereas no association was observed among stage IV patients. Among stage I-III patients, clear dose-response relationships with all survival outcomes were seen for current smokers. For example, current smokers with 40 or more pack-years had statistically significantly worse overall, CRC-specific, and non-CRC-specific survival compared with never smokers (hazard ratio [HR] =1.94, 95% confidence interval [CI] =1.68 to 2.25; HR = 1.41, 95% CI = 1.12 to 1.78; and HR = 2.67, 95% CI = 2.19 to 3.26, respectively). Similar associations with all survival outcomes were observed for former smokers who had quit for less than 10 years, but only a weak association with non-CRC-specific survival was seen among former smokers who had quit for more than 10 years.
This large consortium of CRC patient studies provides compelling evidence that smoking is strongly associated with worse survival of stage I-III CRC patients in a clear dose-response manner. The detrimental effect of smoking was primarily related to noncolorectal cancer events, but current heavy smoking also showed an association with CRC-specific survival.
吸烟与先前研究中的结直肠癌(CRC)发病率和死亡率有关,但目前关于 CRC 诊断后吸烟与生存的证据有限。
我们从国际 CRC 生存分析协作组的 11 项流行病学研究中纳入了 12345 例 I-IV 期 CRC 患者的数据。使用 Cox 比例风险回归模型评估了预测性吸烟行为与总体、CRC 特异性和非 CRC 特异性生存的相关性。
在 12345 例 CRC 患者中,中位随访时间为 7.5 年,有 4379 例(35.5%)死亡(2515 例死于 CRC)。吸烟与 I-III 期患者的生存状况较差密切相关,而在 IV 期患者中未观察到这种相关性。在 I-III 期患者中,当前吸烟者的所有生存结局均呈现明显的剂量反应关系。例如,与从不吸烟者相比,当前吸烟者每日吸烟 40 支或以上且吸烟年数达到 40 年或以上者,其总体、CRC 特异性和非 CRC 特异性生存均显著较差(风险比 [HR] =1.94,95%置信区间 [CI] =1.68 至 2.25;HR = 1.41,95% CI = 1.12 至 1.78;HR = 2.67,95% CI = 2.19 至 3.26)。对于戒烟时间不足 10 年的前吸烟者,所有生存结局均存在相似的相关性,但对于戒烟时间超过 10 年的前吸烟者,仅与非 CRC 特异性生存存在较弱的相关性。
这项大规模 CRC 患者研究协作组提供了强有力的证据,表明吸烟与 I-III 期 CRC 患者的生存状况较差密切相关,呈明显的剂量反应关系。吸烟的有害影响主要与非结直肠癌事件有关,但目前重度吸烟也与 CRC 特异性生存有关。